ImmuCell (ICCC) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rallybio (RLYB) has outperformed ImmuCell (ICCC) over the past year, gaining 268.7% versus a gain of 48.0%. Over five years, ICCC leads with a +5.1% price change compared with -86.3% for RLYB. Rallybio is the larger company by market cap ($91.5 million vs $88.6 million), about 1.0 times the size.
On valuation, Rallybio trades at a lower trailing P/E (2.1x vs 139.3x for ImmuCell).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | RLYB |
|---|---|---|
| Share price | $9.75 | $17.22 |
| Market cap | $88.55M | $91.48M |
| 1-day change | 0.00% | +1.35% |
| YTD return | +58.54% | +209.58% |
| 1-year return | +47.95% | +268.71% |
| 5-year return | +5.06% | -86.32% |
| P/E ratio (TTM) | 139.29 | 2.15 |
| EPS (TTM) | $0.07 | $8.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.10 | $17.57 |
| 52-week low | $4.52 | $3.67 |
| Distance from 52-week high | -19.42% | -2.01% |
| Average volume | 22.20K | 21.33K |
| Shares outstanding | 9.08M | 5.31M |
| Employees | 73 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed ICCC by 220.8 percentage points over the past year.
- ImmuCell trades at a higher earnings multiple (139.3x vs 2.1x trailing P/E).
About ImmuCell
ICCC stock →ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 73 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
ICCC vs RLYB FAQ
Which is bigger, ImmuCell or Rallybio?
Rallybio (RLYB) is larger, with a market capitalization of $91.48M compared with $88.55M for ImmuCell (ICCC).
Which stock has performed better over the past year, ICCC or RLYB?
RLYB returned +268.71% over the past 12 months, compared with +47.95% for ICCC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ICCC or RLYB?
RLYB has the lower trailing P/E at 2.1, versus 139.3 for ICCC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are ImmuCell and Rallybio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for ImmuCell and Biotechnology: Pharmaceutical Preparations for Rallybio.